Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia

Human Vaccines and Immunotherapeutics

Volumn 13, Issue 3, 2017, Pages 613-620

  Dolzhikova, I V ^a   Zubkova, O V ^a   Tukhvatulin, A I ^a   Dzharullaeva, A S ^a   Tukhvatulina, N M ^a   Shcheblyakov, D V ^a   Shmarov, M M ^a   Tokarskaya, E A ^a   Simakova, Y V ^a   Egorova, D A ^a   Scherbinin, D N ^a   Tutykhina, I L ^a   Lysenko, A A ^a   Kostarnoy, A V ^a   Gancheva, P G ^a   Ozharovskaya, T A ^a   Belugin, B V ^a   Kolobukhina, L V ^a   Pantyukhov, V B ^b   Syromyatnikova, S I ^b   Shatokhina, I V ^b   Sizikova, T V ^b   Rumyantseva, I G ^b   Andrus, A F ^b   Boyarskaya, N V ^b   Voytyuk, A N ^b   Babira, V F ^c   Volchikhina, S V ^c   Kutaev, D A ^b   Bel'skih, A N ^b   Zhdanov, K V ^b   Zakharenko, S M ^b   Borisevich, S V ^b   Logunov, D Y ^a   Naroditsky, B S ^a   Gintsburg, A L ^a   more..

^a N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^b Ministry of Defense of the Russian Federation   (Russian Federation)

^c Federal State Budget Institution Main Military Clinical Hospital Named after Academician NN Burdenko of the Ministry of Defence of the Russian Federation   (Russian Federation)

Author keywords

Ad5; Ebola; Ebola virus disease; heterologous vaccination; prime boost; vaccine; VSV; ZEBOV

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREATININE; EBOLA VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN; DRUG CARRIER; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ADULT; ALLERGIC REACTION; ARTHRALGIA; ARTICLE; AXILLA TEMPERATURE; BLOOD CELL COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN ADENOVIRUS 5; IMMUNOGENICITY; INJECTION SITE PAIN; LOSS OF APPETITE; LYMPHADENOPATHY; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RASH; RUSSIAN FEDERATION; SEROCONVERSION; SWELLING; URTICARIA; VESICULOVIRUS; ADENOVIRIDAE; ADOLESCENT; ANIMAL; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETICS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; MIDDLE AGED; MONONUCLEAR CELL; PAIN; PATHOLOGY; VOLUNTEER; YOUNG ADULT;

ADENOVIRIDAE; ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG CARRIERS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EBOLA VACCINES; FEMALE; HEALTHY VOLUNTEERS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PAIN; RUSSIA; VACCINES, SYNTHETIC; VESICULOVIRUS; VOLUNTEERS; YOUNG ADULT;

EID: 85011579453     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1238535     Document Type: Article

References (23)

1. Sanchez A, Geisbert TW, Feldmann H. Filoviridae:Marburg and Ebola viruses. In:Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, editors. Fields virology fifth edition volume 1. Philadelphia (PA):Lippincott Williams & Wilkins; 2007, p. 1409-48.
2. Taylor DJ, Leach RW, Bruenn J. Filoviruses are ancient and integrated into mammalian genomes. BMC Evol Biol 2010; 10:193; PMID:20569424; http://dx.doi.org/10.1186/1471-2148-10-193
3. Geisbert TW. Marburg and Ebola hemorrhagic fever (Filoviruses). In:Bennet JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases eighth edition. Philadelphia (PA):Elsevier; 2015, p 1995-9.
4. World Health Organization. Ebola situation report-21 October 2015. Geneva (Switzerland):World Health Organization; 2015Oct21. http://apps.who.int/ebola/current-situation/ebola-situation-report-21-october-2015#main-content
5. Sridhar S. Clinical development of Ebola vaccines. Ther Adv Vaccines 2015; 3(5–6):125-38; PMID:26668751; http://dx.doi.org/10.1177/2051013615611017
6. Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, Hensley L, Ammendola V, Abbate A, Grazioli F, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 2014; 20(10):1126-9; PMID:25194571
7. Moorthy V, Fast P, Greenwood B. Heterologous prime-boost immunisation in Ebola vaccine development, testing and licensure report of a WHO Consultation held on 21 November 2014. Geneva, Switzerland; 2014. http://www.who.int/immunization/research/meetings_workshops/ebola_primeboost_21nov14/en/
8. Lupton HW, Lambert RD, Bumgardner DL, Moe JB, Eddy GA. Inactivated vaccine for Ebola virus efficacious in guineapig model. Lancet 1980; 2(8207):1294-5; PMID:6108462; http://dx.doi.org/10.1016/S0140-6736(80)92352-1
9. Zhu FC, Hou LH, Li JX, Wu SP, Liu P, Zhang GR, Hu YM, Meng FY, Xu JJ, Tang R, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China:preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 2015; 385(9984):2272-9; PMID:25817373; http://dx.doi.org/10.1016/S0140-6736(15)60553-0
10. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein:interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015; 386(9996):857-66; PMID:26248676; http://dx.doi.org/10.1016/S0140-6736(15)61117-5
11. Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine:a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 2015; 15(10):1156-66; PMID:26248510; http://dx.doi.org/10.1016/S1473-3099(15)00154-1
12. Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, Traore A, Coulibaly F, Kodio M, Onwuchekwa U, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo:a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2016; 16(1):31-42; PMID:26546548; http://dx.doi.org/10.1016/S1473-3099(15)00362-X
13. De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, Estoppey D, Steiner-Monard V, Lonchampt S, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults:a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis 2016; 16(3):311-20; PMID:26725450; http://dx.doi.org/10.1016/S1473-3099(15)00486-7
14. Ledgerwood JE, DeZure AD, Stanley DA, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, Ploquin A, Sitar S, et al. Chimpanzee adenovirus vector Ebola vaccine - preliminary report. N Engl J Med 2014; PMID:25426834; http://dx.doi.org/10.1056/NEJMoa1410863
15. Ledgerwood JE, Sullivan NJ, Graham BS. Chimpanzee adenovirus vector Ebola vaccine–preliminary report. N Engl J Med 2015; 373(8):776; PMID:26287857
16. Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Munoz P, et al. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine—Preliminary Report. N Engl J Med 2015; PMID:25830322; http://dx.doi.org/10.1056/NEJMoa1414216
17. Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 2016; 374(17):1647-60; PMID:25830326; http://dx.doi.org/10.1056/NEJMoa1502924
18. Bengtsson KL, Song H, Stertman L, Liu Y, Flyer DC, Massare MJ, Xu RH, Zhou B, Lu H, Kwilas SA, Hahn TJ, Kpamegan E, Hooper J, Carrion R, Jr, Glenn G, Smith G. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine 2016 Apr 7; 34(16):1927-35; http://dx.doi.org/10.1016/j.vaccine.2016.02.033
19. Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010; 29(2):304-13; PMID:21034824; http://dx.doi.org/10.1016/j.vaccine.2010.10.037
20. Good Safety Information Practices. In:Council for International Organizations of Medical Sciences, author. Guidelines for preparing core clinical-safety information on drugs:report of CIOMS working group III. Geneva (Switzerland):World Health Organization; 1995.
21. Centers for Disease Control and Prevention. Possible side-effects from vaccines. Atlanta (GA):Centers for Disease Control and Prevention; 20 Jul 2016. http://www.cdc.gov/vaccines/vac-gen/side-effects.htm
22. Quah BJ, Warren HS, Parish CR. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc 2007; 2(9):2049-56; PMID:17853860; http://dx.doi.org/10.1038/nprot.2007.296
23. Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV, Shmarov MM, Dolzhikova IV, Stanhope-Baker P, Naroditsky BS, Gudkov AV, Logunov DY, et al. Powerful complex immunoadjuvant based on synergistic effect of combined TLR4 and NOD2 activation significantly enhances magnitude of humoral and cellular adaptive immune responses. PLoS One 2016 11(5):e0155650; PMID:27187797; http://dx.doi.org/10.1371/journal.pone.0155650